Actively Recruiting
StuDy AimED at Increasing AlCohol AbsTinEnce
Led by University of Illinois at Chicago · Updated on 2026-05-07
104
Participants Needed
1
Research Sites
248 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to test the feasibility \& acceptability of an integrated CM-PST intervention (in K99 phase) and preliminary efficacy (in R00 phase), vs. CM alone, to improve treatment efficacy and inform about neural mechanisms of treatment effects in young adults with Alcohol Use Disorder (AUD). The aims are as follows: K99 Aim: Test feasibility \& acceptability of a developed CM-PST, by meeting these benchmarks: 2a Feasibility: enroll 20 participants in the new CM-PST in a single-arm pre- and post-study, and retain ≥85% at wk 12. 2b Deliver CM-PST at ≥90% fidelity to intervention protocol. 2c Acceptability to participants: Achieve mean score ≥3 on Client Satisfaction Scale Questionnaire and satisfaction from semi-structured interviews. R00 Aim 1) Test preliminary efficacy of CM-PST in a 2-arm pilot RCT: Male/female young adults (aged18-24) who meet AUD criteria will be randomized to CM-PST or CM-only control, and assessed at baseline (0), 3, and 6 months. Primary study endpoint will be 3 months. R00 Aim 2 (Exploratory) Explore potential neural mechanisms of CM-PST effects, by fMRI scanning \& analyses of core regions of the brain circuits regulating positive affect (ventral striatum), negative affect (amygdala), and cognitive control (dorsolateral prefrontal cortex), and connectivity between these core regions.
CONDITIONS
Official Title
StuDy AimED at Increasing AlCohol AbsTinEnce
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female young adults aged 18-24 years
- English-speaking
- Current alcohol use at least 1 day per week via phone screening
- Meet criteria for mild, moderate, or severe AUD in the past year on AUDIT and AUDADIS surveys
- Completion of written informed consent
- Attendance at baseline screening visit
You will not qualify if you...
- Participation in alcohol or substance use treatment within the past 6 months
- Current use of medications for AUD such as naltrexone
- Lifetime diagnosis of schizophrenia, bipolar disorder, or any psychotic disorder
- Current use of psychoactive drugs confirmed by positive drug screen
- Conditions interfering with reward functioning measurements (e.g., tic disorder)
- Pregnancy or intention to become pregnant
- For fMRI scan: presence of bodily ferrous metals or claustrophobia preventing scan tolerance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60608
Actively Recruiting
Research Team
H
Hagar Hallihan, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here